Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports ...
A team from the Max-Planck-Institut für Kohlenforschung, Hokkaido University, and Osaka University has discovered that subtle differences in molecular structure can have a major impact on the ...
A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA vaccines generate immunity, revealing that certain non-immune cells help ...
Scientists have discovered the internal shape of tiny drug-delivery particles - called lipid nanoparticles - has a big impact on how well our cells absorb them, paving the way to more efficient ...
A team of researchers has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics. Their study provides the first comprehensive understanding of how mRNA ...
Messenger Ribonucleic Acid (mRNA) vaccines gained global recognition during the Coronavirus Disease 2019 (COVID-19) pandemic, proving their value through rapid development, high efficacy, and broad ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results